---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-035499"
form_type: "8-K"
ticker: "ABVC"
cik: "0001173313"
company_name: "ABVC BIOPHARMA, INC."
filed_at: "2026-03-27T23:59:59+00:00"
generated_at: "2026-05-15T08:33:02.609818+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.15
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# ABVC BioPharma shareholders re-elect 11 directors, ratify auditor, approve equity plan increase at 2026 annual meeting

## Summary
- All 11 incumbent directors re-elected with overwhelming support (over 98% for each nominee).
- Ratification of Simon & Edward, LLP as independent auditor for FY 2026: 10,597,352 for, 12,291 against.
- Equity incentive plan increase approved: 9,964,400 for, 643,419 against; shares reserved now 15% of outstanding.
- Quorum established with 10,612,493 shares (41.74% of voting power) present.

## SEC filing metadata
- accession: 0001213900-26-035499
- form_type: 8-K
- ticker: ABVC
- cik: 0001173313
- company_name: ABVC BIOPHARMA, INC.
- filed_at: 2026-03-27T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.15
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1173313/000121390026035499/0001213900-26-035499-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1173313/000121390026035499/ea028361801-8k_abvcbiopharm.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-035499
- JSON: https://secwatch.observer/filing/0001213900-26-035499.json
- Plain text: https://secwatch.observer/filing/0001213900-26-035499.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.